Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis), but they eventually acquire resistance. Preclinical studies yielded several PARPi resi...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cell reports (Cambridge) Ročník 42; číslo 5; s. 112538
Hlavní autori:	Bhin, Jinhyuk, Paes Dias, Mariana, Gogola, Ewa, Rolfs, Frank, Piersma, Sander R., de Bruijn, Roebi, de Ruiter, Julian R., van den Broek, Bram, Duarte, Alexandra A., Sol, Wendy, van der Heijden, Ingrid, Andronikou, Christina, Kaiponen, Taina S., Bakker, Lara, Lieftink, Cor, Morris, Ben, Beijersbergen, Roderick L., van de Ven, Marieke, Jimenez, Connie R., Wessels, Lodewyk F.A., Rottenberg, Sven, Jonkers, Jos
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 30.05.2023 Cell Press Elsevier
Predmet:	BRCA1 BRCA2 breast cancer CP: Cancer homologous recombination multi-omics PARP inhibitor therapy resistance homologous recombination CP: Cancer PARP inhibitor multi-omics breast cancer BRCA1 BRCA2 therapy resistance
ISSN:	2211-1247, 2211-1247
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!